JY
VERA icon

Jeff Yass’s Vera Therapeutics VERA Stock Holding History

Jeff Yass’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
69,500
+43,200
+164% +$1.61M ﹤0.01% 5627
2026
Q1 		$1.06M Sell
26,300
-2,400
-8% -$103K ﹤0.01% 7750
2025
Q4 		$1.45M Sell
28,700
-62,300
-68% -$2.21M ﹤0.01% 6324
2025
Q3 		$2.64M Sell
91,000
-92,100
-50% -$2.13M ﹤0.01% 5218
2025
Q2 		$4.31M Buy
183,100
+142,100
+347% +$3.2M ﹤0.01% 4263
2025
Q1 		$985K Buy
41,000
+25,100
+158% +$807K ﹤0.01% 7301
2024
Q4 		$672K Sell
15,900
-66,100
-81% -$2.93M ﹤0.01% 7926
2024
Q3 		$3.62M Buy
82,000
+30,200
+58% +$1.15M ﹤0.01% 4188
2024
Q2 		$1.87M Sell
51,800
-15,900
-23% -$631K ﹤0.01% 5216
2024
Q1 		$2.92M Buy
67,700
+51,200
+310% +$1.82M ﹤0.01% 4574
2023
Q4 		$254K Buy
+16,500
New +$210K ﹤0.01% 10185
2023
Q3 		– Sell
-12,600
Closed -$202K – 13060
2023
Q2 		$202K Sell
12,600
-19,000
-60% -$172K ﹤0.01% 10244
2023
Q1 		$245K Buy
+31,600
New +$244K ﹤0.01% 10166

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's VERA Position: Q2 2026 in Review

Jeff Yass increased its Vera Therapeutics (VERA) stake by 33% in Q2 2026, buying an estimated $1.48M and bringing the position to 160,837 shares worth $6.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Jeff Yass first reported a position in VERA in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.95M in Q4 2025. 218 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Jeff Yass held 160,837 shares of Vera Therapeutics worth $6.9M as of Q2 2026.
  • Jeff Yass bought 39,817 Vera Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Vera Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4022 holding.
  • Jeff Yass first reported a position in Vera Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Jeff Yass's Vera Therapeutics position peaked at $8.95M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.